Metsera Inc (MTSR)

$35.87 -0.42 (-1.16%)
Market Cap 3.77B
Revenue (ttm) 0.00
Net Income (ttm) -209.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,521,700
Avg Vol 1,206,122
Day's Range N/A - N/A
Shares Out 105.06M
Stochastic %K 68%
Beta N/A
Analysts Strong Sell
Price Target $59.00

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 784 6595
Website: metsera.com
Address:
3 World Trade Center, 175 Greenwich Street, New York, United States
vu_jade
vu_jade Sep. 5 at 2:35 PM
$MTSR shakeout? Volume looks light
0 · Reply
biolover
biolover Sep. 5 at 3:14 AM
$VKTX $MTSR obesity assets all undervalued now. Just trying to predict data before reporting based on mechanism and CEO statements. Difference is data quality should be good to Viking if my projections turn true. MTSR has elements of strength long term as well.
0 · Reply
biolover
biolover Sep. 4 at 8:51 PM
$VKTX $MTSR on Cantor yesterday. CEO on Vesper1 talking about efficacy of tirzepatide at 28 wks of 13% plc adjusted wt loss ( ahead of data release ) and similar phase 2a n/v ( had vomiting of 60% at 1.2 mg ) But at versper 3 at 12 wk slow escalation he mentioned of tirzapetide type vomiting . .. CEO believes his audience are high school guys where he gets wt loss from a dose with no escalation and high vomiting rate and call it dual agonist efficacy. … but there are no big shorts entrenched yet $LLY $NVO $PFE
2 · Reply
OptionRunners
OptionRunners Sep. 4 at 5:30 PM
$MTSR presenting at the Wells Fargo 2025 Healthcare Conference this afternoon from 4:30-5:05 pm EST
2 · Reply
OptionRunners
OptionRunners Sep. 4 at 5:16 PM
$MTSR Buyer of the February 20th 2026 $45/$25 bull risk reversals 500 times for $2.70
0 · Reply
S2K_TradeZ
S2K_TradeZ Sep. 3 at 9:01 AM
🦉Larger MC Worth Watching Its Momentum: $SOUN, $NEO, $MTSR
1 · Reply
himsssss
himsssss Sep. 2 at 8:57 PM
$MTSR I never talk about a company getting acquired but if I did it would be this one.
4 · Reply
NoBagHoldingENT
NoBagHoldingENT Sep. 1 at 9:08 PM
$MTSR Amylin are prized for their combinability. Amylin clinical stage assets all in the hands of Big Pharma besides this one.
0 · Reply
biolover
biolover Aug. 29 at 5:19 PM
$MTSR $VKTX we known you like Metsera more. Metsera has a number of molecules and moving fast. They have questionable data release in sep. they combined two trials and reporting efficacy from one and tolerability ( and surprisingly not efficacy per their release ) from the other, in this very sensitive biotech era. It’s clear that heavy shorts are not entrenched in MTSR , probably bz it did not reach $10 B Mc in worst biotech times ( which improved ) and it is clear their is some manipulation in its SP. the million dollar question can any one get in and out long term ? If GLP1 class grow as it is doing now ( combined 2 drugs of $17 B per q ) Metsera can clealrh value more. But I still believe long term it will come down to best drug prevailing. And if M&A occurs between now and then. Clearly BP is doing their dd carefully and only care about sales long term
2 · Reply
judgeyoung2
judgeyoung2 Aug. 29 at 4:40 PM
$VKTX $MTSR data should be out any day now. I wonder how it will impact Viking, whether the data is good or bad.
0 · Reply
Latest News on MTSR
Metsera to Present at Upcoming September Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 10 days ago

Metsera to Present at Upcoming September Investor Conferences

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Jul 28, 2025, 4:01 PM EDT - 5 weeks ago

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 7:00 AM EDT - 3 months ago

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Jun 9, 2025, 2:07 PM EDT - 3 months ago

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Jun 9, 2025, 12:04 PM EDT - 3 months ago

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Jun 9, 2025, 7:00 AM EDT - 3 months ago

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Jun 5, 2025, 7:30 AM EDT - 3 months ago

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

May 12, 2025, 7:00 AM EDT - 4 months ago

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Bank of America 2025 Global Healthcare Conference

May 8, 2025, 4:01 PM EDT - 4 months ago

Metsera to Present at Bank of America 2025 Global Healthcare Conference

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Mar 26, 2025, 7:00 AM EDT - 5 months ago

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 7:00 AM EST - 6 months ago

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Feb 26, 2025, 3:55 AM EST - 6 months ago

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Why this newly public biotech could become a force in obesity treatments

Feb 25, 2025, 1:42 PM EST - 6 months ago

Why this newly public biotech could become a force in obesity treatments

This weight-loss drug stock could deliver a 90% return in 2025

Feb 25, 2025, 8:47 AM EST - 6 months ago

This weight-loss drug stock could deliver a 90% return in 2025

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

Feb 5, 2025, 4:01 PM EST - 7 months ago

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 7 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE ODTX ODYS SAIL

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Jan 31, 2025, 12:42 PM EST - 7 months ago

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Weight-loss drug developer Metsera raises $275 million in US IPO

Jan 30, 2025, 7:05 PM EST - 7 months ago

Weight-loss drug developer Metsera raises $275 million in US IPO

Metsera Announces Pricing of Initial Public Offering

Jan 30, 2025, 6:53 PM EST - 7 months ago

Metsera Announces Pricing of Initial Public Offering

Metsera Readies $275 Million IPO For Obesity Treatments

Jan 28, 2025, 4:48 PM EST - 7 months ago

Metsera Readies $275 Million IPO For Obesity Treatments

Weight-loss drug developer Metsera reveals wider loss in US IPO filing

Jan 10, 2025, 6:02 PM EST - 8 months ago

Weight-loss drug developer Metsera reveals wider loss in US IPO filing

Metsera IPO Registration Document (S-1)

Jan 10, 2025, 4:46 PM EST - 8 months ago

Metsera IPO Registration Document (S-1)

vu_jade
vu_jade Sep. 5 at 2:35 PM
$MTSR shakeout? Volume looks light
0 · Reply
biolover
biolover Sep. 5 at 3:14 AM
$VKTX $MTSR obesity assets all undervalued now. Just trying to predict data before reporting based on mechanism and CEO statements. Difference is data quality should be good to Viking if my projections turn true. MTSR has elements of strength long term as well.
0 · Reply
biolover
biolover Sep. 4 at 8:51 PM
$VKTX $MTSR on Cantor yesterday. CEO on Vesper1 talking about efficacy of tirzepatide at 28 wks of 13% plc adjusted wt loss ( ahead of data release ) and similar phase 2a n/v ( had vomiting of 60% at 1.2 mg ) But at versper 3 at 12 wk slow escalation he mentioned of tirzapetide type vomiting . .. CEO believes his audience are high school guys where he gets wt loss from a dose with no escalation and high vomiting rate and call it dual agonist efficacy. … but there are no big shorts entrenched yet $LLY $NVO $PFE
2 · Reply
OptionRunners
OptionRunners Sep. 4 at 5:30 PM
$MTSR presenting at the Wells Fargo 2025 Healthcare Conference this afternoon from 4:30-5:05 pm EST
2 · Reply
OptionRunners
OptionRunners Sep. 4 at 5:16 PM
$MTSR Buyer of the February 20th 2026 $45/$25 bull risk reversals 500 times for $2.70
0 · Reply
S2K_TradeZ
S2K_TradeZ Sep. 3 at 9:01 AM
🦉Larger MC Worth Watching Its Momentum: $SOUN, $NEO, $MTSR
1 · Reply
himsssss
himsssss Sep. 2 at 8:57 PM
$MTSR I never talk about a company getting acquired but if I did it would be this one.
4 · Reply
NoBagHoldingENT
NoBagHoldingENT Sep. 1 at 9:08 PM
$MTSR Amylin are prized for their combinability. Amylin clinical stage assets all in the hands of Big Pharma besides this one.
0 · Reply
biolover
biolover Aug. 29 at 5:19 PM
$MTSR $VKTX we known you like Metsera more. Metsera has a number of molecules and moving fast. They have questionable data release in sep. they combined two trials and reporting efficacy from one and tolerability ( and surprisingly not efficacy per their release ) from the other, in this very sensitive biotech era. It’s clear that heavy shorts are not entrenched in MTSR , probably bz it did not reach $10 B Mc in worst biotech times ( which improved ) and it is clear their is some manipulation in its SP. the million dollar question can any one get in and out long term ? If GLP1 class grow as it is doing now ( combined 2 drugs of $17 B per q ) Metsera can clealrh value more. But I still believe long term it will come down to best drug prevailing. And if M&A occurs between now and then. Clearly BP is doing their dd carefully and only care about sales long term
2 · Reply
judgeyoung2
judgeyoung2 Aug. 29 at 4:40 PM
$VKTX $MTSR data should be out any day now. I wonder how it will impact Viking, whether the data is good or bad.
0 · Reply
Theflash88
Theflash88 Aug. 28 at 7:57 PM
$MTSR Petered out! 2 days in a row.. no gas..
0 · Reply
IN0V8
IN0V8 Aug. 28 at 5:55 PM
$MTSR Buying Opportunity BofA Global Research raises price objective to $50 from $45
0 · Reply
GPTInsights
GPTInsights Aug. 28 at 3:20 PM
$VKTX Just for comparison --- $MTSR has a market cap right now of $3.88 billion and not still working to get phase 2 completed for both their GLP and Amylin drugs which they intend to combine. VKTX has $3.09 billion MC and entering phase 3 for both SC and PO. Can't say for sure but judging on the already existing $NVO Amycretin dual GLP/Amylin - the side effects were very high and it would seem probable MTSR will have the same issues or possibly worse considering their drug seems to be even stronger/longer halflife than Amycretin as they target once monthly dosing. Open to discussion here if anyone wants to weigh in.
0 · Reply
himsssss
himsssss Aug. 28 at 1:48 AM
$MTSR data this week is very likely. Presentation set for September the 3rd.
1 · Reply
Ms_P
Ms_P Aug. 27 at 3:16 PM
$MTSR Anyone know why this is moving up so much today?
1 · Reply
IPOtweet
IPOtweet Aug. 26 at 10:15 AM
LB Pharmaceuticals prepares to break the biotech IPO dry spell $LBRX $AARD $MTSR $BBOT $IPO #IPO https://zpr.io/bkxU5p8RzrTT
0 · Reply
biolover
biolover Aug. 22 at 10:29 PM
$VKTX $MTSR delayed data next months. CEO fire chats. Analysts piling food reviews. Data digestion , Maintenance trail starting this q3. And more important BP looking through data and partnership chatter. Q4 amylin trial. Obesity wk presentation of data and PK. Hopefully a few obesity MD been looking at the data carefully as we summarized and voice confidence. Especially if there is big crowd on poster.
0 · Reply
himsssss
himsssss Aug. 21 at 10:45 PM
$VKTX $MTSR @Bayes_Theorem
0 · Reply
NoBagHoldingENT
NoBagHoldingENT Aug. 21 at 10:43 PM
$VKTX moved to $MTSR with my cash. Differentiation matters a lot with BP. First in class once a month Amylin shot for Metsera and once a month GLP with a combo of both. Lot of data coming from now till end of year and they also have an oral pill asset with early data coming by years end. Viking is still a solid buy. A slightly better Tirzepatide for the shot with a strong pill will be favorable. Its clear imo tho BL will wait till after P3 erases concerns to sell for max value.
3 · Reply
NoBagHoldingENT
NoBagHoldingENT Aug. 20 at 11:24 PM
$VKTX $MTSR $ALT the universe God created has a funny way of humbling all lol. Don't kick others when they are down no matter how minimal the contact is. Could be you tomorrow.
2 · Reply
NoBagHoldingENT
NoBagHoldingENT Aug. 20 at 10:53 PM
$VKTX this and $MTSR are going to be prime buyout targets. I'll buy Viking again and Metsera after the stock decline coming
0 · Reply
Blink182rulez
Blink182rulez Aug. 19 at 4:30 PM
$MTSR $VKTX why is metsera also down big?
0 · Reply